Does cardiology hold pharmacogenetics to an inconsistent standard? A comparison of evidence among recommendations. (10th September 2018)

• Record Type: Journal Article
• Authors: Luzum, Jasmine A; Cheung, Jason C
• Is Part Of: Pharmacogenomics. Volume 19:Number 15(2018)
• Page Start: 1203
• Page End: 1216
• Publication Date: 2018-09-10
• Subjects: American Heart Association/American College of Cardiology -- clopidogrel -- epidermal growth factor receptor inhibitors -- guidelines -- long QT syndrome -- National Comprehensive Cancer Network -- pharmacogenetics -- recommendations -- thiopurines; Pharmacogenomics -- Periodicals; 615.1
• DOI: 10.2217/pgs-2018-0097
• Languages: English
• ISSNs: 1462-2416

Abstract

Current guideline recommendations for pharmacogenetic testing for clopidogrel by the American Heart Association/American College of Cardiology (AHA/ACC) contradict the Clinical Pharmacogenetics Implementation Consortium and the US FDA. The AHA/ACC recommends against routine pharmacogenetic testing for clopidogrel because no randomized controlled trials have demonstrated that testing improves patients' outcomes. However the AHA/ACC and the National Comprehensive Cancer Network (NCCN) recommend other pharmacogenetic tests in the absence of randomized controlled trials evidence. Using clopidogrel as a case example, we compared the evidence for other pharmacogenetic tests recommended by the AHA/ACC and NCCN. In patients that received percutaneous coronary intervention, the evidence supporting pharmacogenetic testing for clopidogrel is stronger than other pharmacogenetic tests recommended by the AHA/ACC and NCCN.